Sugi Predict

Sugi Predict / Compounds / SCHEMBL9609628

SCHEMBL9609628

SCHEMBL9609628

Cc1cc(N)cc(-n2ccnc2)c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 1/20 0.55
▸ MAPT P10636 1/20 0.55
▸ CYP3A4 P08684 3/20 0.44
▸ TSHR P16473 2/20 0.43
▸ ALDH1A1 P00352 1/20 0.43
▸ CYP11B1 P15538 5/20 0.42
▸ CYP11B2 P19099 5/20 0.42
▸ ENPP2 Q13822 1/20 0.42
▸ MKNK1 Q9BUB5 1/20 0.42
▸ MKNK2 Q9HBH9 1/20 0.42
▸ NOTUM Q6P988 1/20 0.42
▸ IDO1 P14902 2/20 0.41
▸ CYP19A1 P11511 2/20 0.41
▸ CYP2A6 P11509 1/20 0.41
▸ BAZ2B Q9UIF8 1/20 0.40
▸ MEN1 O00255 1/20 0.40
▸ ALOX15 P16050 1/20 0.40
▸ KMT2A Q03164 1/20 0.40
▸ PDE3B Q13370 1/20 0.38
▸ PDE3A Q14432 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30880680 1.00 LMNA (0.55) LMNAMAPTCYP3A4TSHRALDH1A1
SCHEMBL872411 0.91 LMNA (0.53) LMNAMAPTCYP3A4TSHRCYP11B1
SCHEMBL18288736 0.87 CYP3A4 (0.52) LMNAMAPTCYP3A4TSHRCYP11B1
SCHEMBL10760976 0.79 LMNA (0.41) LMNAMAPTCYP3A4CYP11B1CYP11B2
SCHEMBL25492424 0.79 ENPP2 (0.55) LMNAMAPTCYP3A4TSHRALDH1A1
SCHEMBL18282264 0.79 CYP11B1 (0.47) LMNAMAPTCYP3A4TSHRCYP11B1
SCHEMBL30880594 0.78 CYP11B1 (0.59) LMNAMAPTCYP3A4CYP11B1CYP11B2
SCHEMBL30880480 0.78 CYP11B1 (0.59) LMNAMAPTCYP3A4CYP11B1CYP11B2
SCHEMBL15315529 0.76 MAP3K5 (0.42) LMNAMAPTCYP3A4TSHRALDH1A1
SCHEMBL16673120 0.76 CYP3A4 (0.62) LMNAMAPTCYP3A4TSHRCYP11B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024078513-A1 CONDENSED AZINES FOR TREATING CANCER CHENGDU ANTICANCER BIOSCIENCE , LTD. (CN) 2024-04-18 — — WO disclosed
US-20170369446-A1 MONOCYCLIC HETEROARYL COMPOUNDS ARIAD PHARMA INC (US) 2017-12-28 — — US disclosed
US-20160368917-A1 Bicyclic Heteroaryl Compounds ARIAD PHARMA INC (US) 2016-12-22 — — US disclosed
US-9278971-B2 Substituted acetylenic pyrazolo[1,5-a]pyrimidines as kinase inhibitors ARIAD PHARMACEUTICALS, INC. (US) 2016-03-08 — — US disclosed
US-9090561-B2 Acetylenic heteroaryl compounds ARIAD PHARMACEUTICALS, INC. (US) 2015-07-28 — — US disclosed
US-9029533-B2 Substituted acetylenic imidazo[1,2-A]pyridazines as kinase inhibitors ARIAD PHARMACEUTICALS, INC. (US) 2015-05-12 — — US disclosed
US-20150105377-A1 Methods and Compositions for RAF Kinase Mediated Diseases ARIAD PHARMACEUTICALS, INC. 2015-04-16 — — US disclosed
US-20140288082-A1 Bicyclic Heteroaryl Compounds TAKEDA PHARMACEUTICALS U.S.A., INC. 2014-09-25 — — US disclosed
US-20140066434-A1 Methods and Compositions for Treating Parkinson's Disease ARIAD PHARMACEUTICALS, INC. (US) 2014-03-06 — — US disclosed
US-20140045826-A1 METHODS AND COMPOSITIONS FOR TREATING NEURODEGENERATIVE DISEASES ARIAD PHARMACEUTICALS, INC. (US) 2014-02-13 — — US disclosed
US-20130231337-A1 Bicyclic Heteroaryl Compounds ARIAD PHARMACEUTICALS, INC. (US) 2013-09-05 — — US disclosed
US-8470851-B2 Substituted acetylenic imidazo[1,2-A]pyridine compounds as kinase inhibitors ARIAD PHARMACEUTICALS, INC. (US) 2013-06-25 — — US disclosed
US-20130018046-A1 Acetylenic Heteroaryl Compounds ARIAD PHARMACEUTICALS, INC. (US) 2013-01-17 — — US disclosed
US-20130005738-A1 Monocyclic Heteroaryl Compounds ARIAD PHARMACEUTICALS, INC. (US) 2013-01-03 — — US disclosed
US-20120135986-A1 Bicyclic Heteroaryl Compounds ARIAD PHARMACEUTICALS, INC. (US) 2012-05-31 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130005738-A1 Monocyclic Heteroaryl Compounds CYP3A43, CYP2F1, CYP11B2 LMNA 2823/4885MAPT 1488/4885CYP3A4 11/4885
US-20140066434-A1 Methods and Compositions for Treating Parkinson's Disease PARK7, SNCA, HTT LMNA 2338/4885MAPT 12/4885CYP3A4 2557/4885
US-20160368917-A1 Bicyclic Heteroaryl Compounds CYP3A43, CYP11B2, CYP2F1 LMNA 2011/4885MAPT 2300/4885CYP3A4 14/4885
US-20130018046-A1 Acetylenic Heteroaryl Compounds NAT1, AADAC, ACACA LMNA 2095/4885MAPT 1839/4885CYP3A4 48/4885
US-20150105377-A1 Methods and Compositions for RAF Kinase Mediated Diseases BRAF, RAF1, NRAS LMNA 1502/4885MAPT 1554/4885CYP3A4 4549/4885
US-20140045826-A1 METHODS AND COMPOSITIONS FOR TREATING NEURODEGENERATIVE DISEASES HTT, MAPT, SNCA LMNA 471/4885MAPT 2/4885CYP3A4 4159/4885
US-20140288082-A1 Bicyclic Heteroaryl Compounds CYP3A43, CYP11B2, CYP2F1 LMNA 2011/4885MAPT 2300/4885CYP3A4 14/4885
US-20170369446-A1 MONOCYCLIC HETEROARYL COMPOUNDS CYP3A43, CYP2F1, CYP11B2 LMNA 2823/4885MAPT 1488/4885CYP3A4 11/4885
US-20130231337-A1 Bicyclic Heteroaryl Compounds CYP3A43, CYP11B2, CYP2F1 LMNA 2011/4885MAPT 2300/4885CYP3A4 14/4885
US-20120135986-A1 Bicyclic Heteroaryl Compounds CYP3A43, CYP11B2, CYP2F1 LMNA 2011/4885MAPT 2300/4885CYP3A4 14/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.